|Dr. Christopher R. Anzalone Ph.D.||CEO, Pres & Director||1.06M||N/A||48|
|Mr. Kenneth A. Myszkowski MBA, CPA||Chief Financial Officer||476.13k||119.8k||51|
|Dr. Bruce D. Given M.D.||Chief Operating Officer||694.03k||N/A||63|
|Mr. Patrick O'Brien J.D., PharmD||Gen. Counsel||571.93k||N/A||53|
|Dr. Mark M. Davis Ph.D.||Founder and Founder & Director of Insert Therapeutics Inc & Calando||N/A||N/A||N/A|
Arrowhead Pharmaceuticals, Inc. develops novel drugs to treat intractable diseases in the United States. Its pre-clinical stage drug candidates include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT to treat liver disease associated with alpha-1 antitrypsin deficiency; ARO-LPA to reduce production of apolipoprotein A; ARO-AMG1, which is developed against an undisclosed genetically validated cardiovascular target; and ARO-F12, a potential treatment for factor 12 mediated diseases, such as hereditary angioedema and thromboembolic disorders. The company also develops ARO-HIF2, a drug candidate for the treatment of clear cell renal cell carcinoma. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreements with Amgen, Inc. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Arrowhead Pharmaceuticals, Inc.’s ISS Governance QualityScore as of July 1, 2017 is 7. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 6; Compensation: 7.